Previous 10 | Next 10 |
Data published in Drugs in R&D confirms extended-release PK profile of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with shoulder OA Plasma PK data indicate the total and maximal exposure to triamcinolone acetonide (TA) was approximat...
The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Flexion Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
Flexion Therapeutics, Inc. (FLXN) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications and Investor Relations Michael Clayman - Chief Executive Officer Melissa Layman - Chief Commercial Officer Fred Driscoll - C...
Image source: The Motley Fool. Flexion Therapeutics, inc (NASDAQ: FLXN) Q2 2021 Earnings Call Aug 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Flexion Therapeutics, inc (FLXN) Q2 2021 Earnings Call Transcript ...
Flexion Therapeutics (NASDAQ:FLXN): Q2 GAAP EPS of -$0.44 beats by $0.06. Revenue of $28.2M (+82.5% Y/Y) misses by $0.74M. Flexion reiterates full-year 2021 ZILRETTA net sales guidance in the range of $120 million to $130 million (vs. consensus $125.54M) Press Release For further details se...
ZILRETTA® ( triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarter Net loss in Q2 2021 decreased by $10.4 million (32%), as compared to Q2 2020, during t...
Miller Opportunity Equity gained 3.81% (net of fees) in the second quarter, lagging the S&P 500's 8.55% return. At the beginning of 2021, we estimated ~65% upside in the portfolio. Year-to-date through June 30, 2021, we delivered returns of 20.59% (net) and currently estimate the ...
BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET. A live webcast of the...
Flexion Therapeutics continues to report steady revenue growth as ZILRETTA moves deeper into commercialization. Despite the ongoing pandemic, Flexion reported encouraging Q1 earnings. ZILRETTA's commercial numbers are improving which has encouraged Flexion's management to reiterate th...
Flexion Therapeutics (FLXN) announces the appointment of Utpal Koppikar to the company's board of directors.Koppikar, Chief Financial Officer of Atara Biotherapeutics, will serve as the chair of Flexion’s audit committee.Prior to his tenure with Atara, Koppikar held...
News, Short Squeeze, Breakout and More Instantly...
Flexion Therapeutics Inc. Company Name:
FLXN Stock Symbol:
NASDAQ Market:
Flexion Therapeutics Inc. Website:
-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc...